title: Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen.
abstract: Recently, we reported a highly active regimen in advanced gastric cancer including a weekly administration of cisplatin, epidoxorubicin, leucovorin, 5-fluorouracil with the support of filgrastim. In order to simplify the administration and to decrease the toxicity of these drugs, mainly epidoxorubicin-induced alopecia, we designed a regimen including an infusional 5-fluorouracil schedule according to the de Gramont regimen, cisplatin and mitomycin C replacing epidoxorubicin. Forty-five patients with advanced or metastatic gastric cancer were treated with cisplatin 50 mg m(-2) i.v. on day 1, every 2 weeks, 6S-stereoisomer-leucovorin 100 mg m(-2) i.v. followed by 5-fluorouracil 400 mg m(-2) i.v. bolus and 600 mg m(-2) i.v. in a 22-h infusion, on days 1 and 2, every 2 weeks, and mitomycin C 7 mg m(-2) i.v. bolus on day 2, every 6 weeks. Grades 3-4 toxicities (National Cancer Institute-Common Toxicity Criteria) consisted mainly of neutropenia and thrombocytopenia. Five patients had a complete response and 16 had a partial response for an overall response rate of 46.7% (95% confidence interval, 32.1-61.2%). The median survival was 11 months. The combination of cisplatin, 5-fluorouracil and leucovorin according to de Gramont, and mitomycin C seems to be an active and safe regimen in the treatment of advanced gastric cancer. Because of its low cost it may be suggested for patients not enrolled into clinical trials.
authors.affiliation: Department of Medical Oncology, V.le Gramsci 14, 43100 Parma, Italy. cascinu@yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Cascinu
authors.forename: A M
authors.initials: AM
authors.lastname: Baldelli
authors.forename: V
authors.initials: V
authors.lastname: Catalano
authors.forename: P
authors.initials: P
authors.lastname: Giordani
authors.forename: G D
authors.initials: GD
authors.lastname: Beretta
authors.forename: R R
authors.initials: RR
authors.lastname: Silva
authors.forename: G
authors.initials: G
authors.lastname: Gasparini
authors.forename: D
authors.initials: D
authors.lastname: Mari
authors.forename: R
authors.initials: R
authors.lastname: Maisano
authors.forename: S
authors.initials: S
authors.lastname: Salvagni
authors.forename: S
authors.initials: S
authors.lastname: Barni
authors.forename: R
authors.initials: R
authors.lastname: Labianca
authors.forename: L
authors.initials: L
authors.lastname: Frontini
authors.forename: C
authors.initials: C
authors.lastname: Curti
authors.forename: G
authors.initials: G
authors.lastname: Catalano
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D002945:Cisplatin; D005472:Fluorouracil